Literature DB >> 23614619

SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.

Carina Preskill1, Joanne B Weidhaas.   

Abstract

Single-nucleotide polymorphisms within microRNA (miRNA) binding sites comprise a novel genre of cancer biomarkers. Since miRNA regulation is dependent on sequence complementarity between the mRNA transcript and the miRNA, even single-nucleotide aberrations can have significant effects. Over the past few years, many examples of these functional miRNA binding site SNPs have been identified as cancer biomarkers. While most of the research to date focuses on associations with cancer risk, more and more studies are linking these SNPs to cancer prognosis and response to treatment as well. This review summarizes the state of the field and draws importance to this rapidly expanding area of cancer biomarkers.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23614619      PMCID： PMC4028830          DOI： 10.1615/critrevoncog.2013007254

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN： 0893-9675


  64 in total

1.  C-T variant in a miRNA target site of BCL2 is associated with increased risk of human papilloma virus related cervical cancer--an in silico approach.

Authors:  G Reshmi; Ramachandran Surya; V T Jissa; P S Saneesh Babu; N R Preethi; W S Santhi; P G Jayaprakash; M Radhakrishna Pillai
Journal:  Genomics       Date:  2011-06-17       Impact factor: 5.736

2.  A functional polymorphism at microRNA-629-binding site in the 3'-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population.

Authors:  Lei Yang; Yinyan Li; Mei Cheng; Dongsheng Huang; Jian Zheng; Bin Liu; Xiaoxuan Ling; Qingchu Li; Xin Zhang; Weidong Ji; Yifeng Zhou; Jiachun Lu
Journal:  Carcinogenesis       Date:  2011-11-22       Impact factor: 4.944

3.  A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance.

Authors:  Yuan Wu; Yuzhong Xiao; Xiaofeng Ding; Yiming Zhuo; Peng Ren; Chang Zhou; Jianlin Zhou
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

4.  A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.

Authors:  Kim M Smits; Trupti Paranjape; Sunitha Nallur; Kim A D Wouters; Matty P Weijenberg; Leo J Schouten; Piet A van den Brandt; Fred T Bosman; Joanne B Weidhaas; Manon van Engeland
Journal:  Clin Cancer Res       Date:  2011-10-12       Impact factor: 12.531

5.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

6.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

7.  Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.

Authors:  Annika Brendle; Haixin Lei; Andreas Brandt; Robert Johansson; Kerstin Enquist; Roger Henriksson; Kari Hemminki; Per Lenner; Asta Försti
Journal:  Carcinogenesis       Date:  2008-06-10       Impact factor: 4.944

8.  A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women.

Authors:  Sandrine Tchatchou; Anke Jung; Kari Hemminki; Christian Sutter; Barbara Wappenschmidt; Peter Bugert; Bernhard H F Weber; Dieter Niederacher; Norbert Arnold; Raymonda Varon-Mateeva; Nina Ditsch; Alfons Meindl; Rita K Schmutzler; Claus R Bartram; Barbara Burwinkel
Journal:  Carcinogenesis       Date:  2008-11-20       Impact factor: 4.944

9.  The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.

Authors:  Robert Pilarski; Divya A Patel; Jeffrey Weitzel; Terri McVeigh; Jemima J Dorairaj; Helen M Heneghan; Nicola Miller; Joanne B Weidhaas; Michael J Kerin; Megan McKenna; Xifeng Wu; Michelle Hildebrandt; Daniel Zelterman; Sharon Sand; Lee P Shulman
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

10.  A microRNA-7 binding site polymorphism in HOXB5 leads to differential gene expression in bladder cancer.

Authors:  Junhua Luo; Qingqing Cai; Wei Wang; Hui Huang; Hong Zeng; Wang He; Weixi Deng; Hao Yu; Eddie Chan; Chi-fai Ng; Jian Huang; Tianxin Lin
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240
View more
  16 in total

1.  Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population.

Authors:  Nevena Kotarac; Zorana Dobrijevic; Suzana Matijasevic; Dusanka Savic-Pavicevic; Goran Brajuskovic
Journal:  Pathol Oncol Res       Date:  2020-06-17       Impact factor: 3.201

2.  Focusing the management of rectal cancer.

Authors:  Rachel Dbeis; Neil J Smart; Ian R Daniels
Journal:  Ann Transl Med       Date:  2016-12

Review 3.  Role of microRNAs in the trabecular meshwork.

Authors:  Pedro Gonzalez; Guorng Li; Jianming Qiu; Jing Wu; Coralia Luna
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-02       Impact factor: 2.671

Review 4.  Role of 3'-untranslated region translational control in cancer development, diagnostics and treatment.

Authors:  Andrii Vislovukh; Thaiz Rivera Vargas; Anna Polesskaya; Irina Groisman
Journal:  World J Biol Chem       Date:  2014-02-26

Review 5.  Non-coding RNA networks in cancer.

Authors:  Eleni Anastasiadou; Leni S Jacob; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2017-11-24       Impact factor: 60.716

6.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 7.  MicroRNAome genome: a treasure for cancer diagnosis and therapy.

Authors:  Ioana Berindan-Neagoe; Paloma del C Monroig; Barbara Pasculli; George A Calin
Journal:  CA Cancer J Clin       Date:  2014-08-07       Impact factor: 508.702

8.  SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.

Authors:  P El Hajj; D Gilot; M Migault; A Theunis; L C van Kempen; F Salés; H Fayyad-Kazan; B Badran; D Larsimont; A Awada; L Bachelot; M-D Galibert; G Ghanem; F Journe
Journal:  Br J Cancer       Date:  2015-06-11       Impact factor: 7.640

9.  Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer.

Authors:  Bongyong Lee; Jian-Liang Li; John Marchica; Mark Mercola; Vipul Patel; Ranjan J Perera
Journal:  J Hum Genet       Date:  2021-06-08       Impact factor: 3.172

10.  Identification of a new target of miR-16, Vacuolar Protein Sorting 4a.

Authors:  Neeta Adhikari; Weihua Guan; Brian Capaldo; Aaron J Mackey; Marjorie Carlson; Sundaram Ramakrishnan; Dinesha Walek; Manu Gupta; Adam Mitchell; Peter Eckman; Ranjit John; Euan Ashley; Paul J Barton; Jennifer L Hall
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.